Here are the 10-K annual reports from Cencora, Inc. (COR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow COR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COR filings page.
Cencora, Inc. is a large global pharmaceutical sourcing and distribution company serving healthcare providers and drug manufacturers across human and animal health. It distributes branded, specialty, and generic drugs and provides services such as data analytics, reimbursement support, logistics, pharmacy management, and packaging.
In fiscal 2025, the company continued to execute a strategy focused on its core U.S. and international distribution businesses while expanding higher-margin manufacturer services. Cencora acquired an 85% stake in Retina Consultants of America for $4,042.0 million in cash plus contingent consideration tied to equity units and future business objectives, and it previously invested $718.4 million for a 34.9% interest in oncology joint venture OneOncology.
Customer concentration is significant: Walgreens and Boots generated about 25% of revenue and roughly 38% of accounts receivable, while Evernorth Health Services contributed about 13% of revenue. The top 10 customers represented approximately 66% of revenue. Cencora is reorganizing its reporting into U.S. Healthcare Solutions, International Healthcare Solutions, and Other, and highlights extensive regulatory, litigation, cybersecurity, and geopolitical risks. The company reports more than 51,000 employees worldwide and emphasizes talent development, safety, and broad benefit programs.